The USFDA has approved the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, called teclistamab-cqyv , for treating relapsed or refractory multiple myeloma in adult patients who have already received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody but not received prior BCMA-targeted therapy. Efficacy of teclistamab-cqyv The efficacy of the drug was evaluated in a single-arm, multi-cohort, open-label, multi-center study consisting of 110 patients.
Among the responders, the estimated duration of response (DOR) rate was found to be 90.6% at six months and 66.5% at nine months on a median follow-up of 7.4 months. Recommended dose The recommended dose of teclistamab-cqyv (administered by means of subcutaneous injection) is 0.06 mg/kg, 0.3 mg/kg, and 1.5 mg/kg on days one,…
